Nova Eye MedicalASX:EYE +2.44%55 Median PS Value is A$0.19 as of Jun. 28, 2026, which is 100% below its 10-year median of 1.82. GuruFocus rates ASX:EYE with a GF Score™ of 55/100 and a GF Value™ of A$0.18 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 337 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 65.58% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Nova Eye Medical's Median PS Value or its related term are showing as below:
ASX:EYE'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55 Med: 1.82 Max: 9.46
Current: 0.55
During the past 13 years, the highest Price to Median PS Value of Nova Eye Medical was 9.46. The lowest was 0.55. And the median was 1.82.
ASX:EYE's Price-to-Median-PS-Value is ranked better than 65.58% of 337
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs ASX:EYE: 0.55
Nova Eye Medical (ASX:EYE) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Nova Eye Medical's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.105
/
0.19
=
0.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical Median PS Value Related Terms
Nova Eye Medical Median PS Value Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EYE vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, Nova Eye Medical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.5702.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.121.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ASX:EYE) has a Median PS Value of A$0.19 as of Jun. 28, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nova Eye Medical and its competitors. This is 90% below median its historical median of 1.82. Over the past decade, Nova Eye Medical's Median PS Value has ranged from 0.55 to 9.46. According to the industry distribution chart, Nova Eye Medical ranks #116 out of 337 companies in the Medical Devices & Instruments industry, placing it in the top 34.4%.
Is Nova Eye Medical's Median PS Value too high?
Nova Eye Medical's current Median PS Value of A$0.19 is 90% below median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 9.46. Based on the distribution chart, Nova Eye Medical ranks #116 out of 337 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nova Eye Medical has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #116 out of 337 companies for Median PS Value. This puts Nova Eye Medical in the upper half of its industry. The industry median Median PS Value is 0.71. Historically, Nova Eye Medical's own Median PS Value has ranged from 0.55 to 9.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current Median PS Value is A$0.19, which is 90% below median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Based on GuruFocus' analysis, Nova Eye Medical (ASX:EYE) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.18, compared to a current price of A$0.11 — trading 41.7% below its estimated fair value. The current Median PS Value is A$0.19, which is 90% below median its 10-year median of 1.82. Nova Eye Medical's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Nova Eye Medical (ASX:EYE), the current Median PS Value is A$0.19 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ASX:EYE) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of A$0.11 is trading 41.7% below its estimated GF Value™ of A$0.18.
GuruFocus considers Nova Eye Medical to be Possible Value Trap.
Key valuation signals for ASX:EYE:
Median PS Value: A$0.19 (90% below median its 10-year median of 1.82)
GF Value™: A$0.18 vs. price of A$0.11 (41.7% below fair value)
No single metric tells the full story. See the ASX:EYE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
55GF Score
Get the complete analysis for ASX:EYE
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EYE has been successfully added to your 
